- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00948467
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Michigan
-
Detriot, Michigan, Estados Unidos, 48201
- Wayne State University Karmanos Cancer Institute
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- 18 years or older.
- Have one of the following diagnoses: a nonhematologic malignancy for which standard, curative, or life-prolonging treatment does not exist or is no longer effective; OR have stage 3 or stage 4 unresectable melanoma not priorly treated with either MEK or BRAF inhibitor therapy.
- Melanoma patients should have the V600E BRAF mutation status of their tumor documented, if available, and tumor tissue must be provided for confirmatory genotyping by a central laboratory.
- Have a radiographically or clinically evaluable tumor.
- Have suitable venous access for the conduct of blood sampling.
- Provide voluntary written consent, which can be withdrawn by the patient at any time.
- Female patients who: are post-menopausal for at least 1 year before screening; OR are surgically sterile; OR if they are of childbearing potential agree to practice two effective methods of birth control from the time of signing the informed consent form through 30 days after the last dose of the study drug, or agree to completely abstain from heterosexual intercourse.
- Male patients, even if surgically sterilized, must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of the study drug; OR agree to completely abstain from heterosexual intercourse.
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
- Female patients who are lactating or have a positive serum pregnancy test during the Screening period.
- Antineoplastic therapy or radiotherapy within 21 days; or nitrosoureas of mitomycin C within 42 days
- Prior biologic or immunotherapy ≤ 4 weeks prior to enrollment.
- Grade 2 or greater unresolved toxicity (except alopecia) from previous anticancer therapy.
- Major surgery within 14 days of the first dose of the study drug.
- An active infection requiring systemic therapy; or other severe infection.
- Symptomatic brain metastases.
- Inability to meet specific laboratory test standards during the Screening period as specified in the study protocol.
- Human Immunodeficiency (HIV) positive.
- Hepatitis B surface antigen positive or active hepatitis C infection.
- Serious medical or psychiatric illness likely to interfere with the study.
- Uncontrolled cardiovascular condition.
- Abnormalities on 12-lead ECG performed within 28 days before the start of the study drug that are considered to be clinically significant or rate corrected QT interval > 470 milliseconds.
- Melanoma patients will be excluded if they have had a diagnosis with or treatment for another malignancy within 2 years of the first dose of the study drug, or have been previously diagnosed with another malignancy with any evidence of residual disease.
- Treatment with any investigational product within 28 days before the first dose of the study drug.
- A history of an ongoing or newly diagnosed eye abnormality, such as retinal or corneal pathologies.
- Abnormal left ventricular ejection fraction (LVEF).
- Receiving therapeutic anticoagulation
- Treatment with any of the following strong CYP3A inhibitors or inducers within 14 days before the first dose of study drug: ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, rifampin, rifapentine, or rifabutin.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: TAK-733
|
The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days. The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Safety profile, dose-limiting toxicities, maximum tolerated dose and recommended phase 2 dose of TAK-733
Prazo: 12 months
|
12 months
|
Pharmacokinetic characterization of TAK-733
Prazo: 12 months
|
12 months
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Effect of food on the pharmacokinetics of TAK-733
Prazo: 12 months
|
12 months
|
Antitumor activity of TAK-733 in patients with advanced nonhematologic malignancies
Prazo: 12 months
|
12 months
|
Antitumor activity of TAK-733 in melanoma patients
Prazo: 12 months
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- C20001
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Melanoma metastático avançado
-
Advanced BionicsConcluídoPerda auditiva severa a profunda | em usuários adultos do Advanced Bionics HiResolution™ Bionic Ear SystemEstados Unidos
-
Novartis PharmaceuticalsRecrutamentoAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal Squamous CellCancer (SCC),Head/Pneck SCC,MelanomaHolanda, Republica da Coréia, Espanha, Taiwan, Japão, Itália, Canadá, Estados Unidos, Cingapura
Ensaios clínicos em TAK-733
-
Aegerion Pharmaceuticals, Inc.ConcluídoHipercolesterolemia familiarEstados Unidos, Canadá, Itália, África do Sul
-
Aegerion Pharmaceuticals, Inc.ConcluídoHiperlipidemiaEstados Unidos
-
Aegerion Pharmaceuticals, Inc.FDA Office of Orphan Products DevelopmentConcluídoHipercolesterolemia familiar homozigóticaEstados Unidos, Canadá, Itália, África do Sul
-
Aegerion Pharmaceuticals, Inc.University of Pennsylvania; Doris Duke Charitable FoundationConcluídoHipercolesterolemia familiar homozigóticaEstados Unidos
-
Aegerion Pharmaceuticals, Inc.ConcluídoHipercolesterolemiaEstados Unidos
-
TakedaConcluído
-
TakedaRescindidoTranstorno de Déficit de Atenção/HiperatividadeEstados Unidos
-
TakedaRescindidoDoença cardiovascular | Diabetes tipo 2Estados Unidos, França, Polônia, Ucrânia, Alemanha, Hong Kong, Taiwan, Argentina, Israel, México, Bulgária, Malásia, Romênia, Canadá, Republica da Coréia, Nova Zelândia, Peru, Estônia, Filipinas, Federação Russa, República Checa, Hu... e mais